FDA Oversight of Clinical Trials Described as 'Grossly Inadequate'

THURSDAY, Nov. 17, 2022 -- The U.S. Food and Drug Administration oversight of clinical trials has been described by experts as "grossly inadequate," according to an article published online Nov. 16 in The BMJ.
Following complaints to the FDA...